Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of Renal Cell Carcinoma with a documented clear cell component (ccRCC).
- Currently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab.
- Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a second scan which is at least 4 weeks apart from the previous scan.
- At least one extra-renal measurable target lesion meeting the criteria of RECIST Version 1.1.
- Agree to use contraception from screening, through the study, and for at least 5 months after the last dose of nivolumab as follows: for women of childbearing potential agree to use highly-effective contraceptive methods; for males, agree to use a condom with sexual partner.
Exclusion Criteria:
- Pregnant or nursing.
- Life expectancy of less than 3 months.
- Performance status greater than or equal to (≥) 2 (Eastern Cooperative Oncology Group [ECOG] criteria).
- New York Heart Association (NYHA) Class III or IV, uncontrolled hypertension, or clinically significant arrhythmia.
- Previously received X4P-001.
- Has a second malignancy. Except: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.
- Has active central nervous system (CNS) metastases (including evidence of cerebral edema by Magnetic Resonance Imaging [MRI], or progression from prior imaging study, or any requirement for steroids, or clinical symptoms of/from CNS metastases) within 28 days prior to study treatment. Subjects with known CNS metastases must have a baseline MRI scan within 28 days of study treatment.
- Ongoing clinical adverse events National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade greater than (>) 2 resulting from prior cancer therapies.
- Known history of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS); or positive test for hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg).
- History of clinically significant or uncontrolled cardiac, hepatic, or pulmonary disease.
- Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.
- Inadequate hematologic, hepatic, or renal function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: X4P-001 Plus Nivolumab
Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks.
Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
|
X4P-001 will be administered as per the dose and schedule specified in the arm.
Nivolumab will be administered as per the dose and schedule specified in the arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Drug-related TEAEs: TEAEs with possible, probable, definite, or missing relationship to study medication (X4P-001 or Nivolumab).
Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
TEAEs were defined as events occurring on or after the first dose of study drug through 30 days after the last dose.
Any TEAEs included both serious and non-serious TEAEs.
A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in Reported AE section.
|
From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using reversed-phase high performance liquid chromatography (RP-HPLC) with tandem mass spectrometry (MS) detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
|
Minimum Plasma Concentration (Cmin) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
|
Time to Reach Cmax (Tmax) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
|
Objective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR).
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to less than (<) 10 millimeters (mm).
PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
|
Duration of Objective Response (DOR), Evaluated Using RECIST Version 1.1
Time Frame: Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)
|
DOR was defined as the time from first CR or PR whichever comes first until the time of disease progression by RECIST v1.1 or death due to any cause.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions.
The appearance of 1 or more new lesions was also considered progression.
|
Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)
|
|
Time to Objective Response, Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)
|
Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever comes first.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)
|
|
Disease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
Disease control rate was defined as percentage of participants with best overall response of CR or PR or SD.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions.
The appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
|
Progression Free Survival (PFS), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)
|
PFS was defined as the time from first administration of study medication until objective tumor progression or death from any cause.
Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)
|
|
Time to Progression (TTP), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)
|
TTP was defined as the time from first administration of study medication until objective tumor progression.
Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Chief Medical Officer, X4 Pharmaceuticals, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
Other Study ID Numbers
- X4P-001-RCCB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.